Clinical and laboratory changes produced by piroxicam in rheumatoid arthritis.
Twenty-five patients with active rheumatoid arthritis received treatment with piroxicam during 12 weeks in an open, non-comparative trial. In addition to improvement of clinical parameters, a significant diminution of the erythrocyte sedimentation rate and a decrease in rheumatoid factor titers was noted in both serum and synovial fluid.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010894:Piroxicam; D012217:Rheumatoid Factor / Q000378:metabolism; D013582:Synovial Fluid / Q000378:metabolism; D013843:Thiazines / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D013843:Thiazines; D010894:Piroxicam; D012217:Rheumatoid Factor